The label for Ozempic (semaglutide) was revised on 2026-05-19 to include a new boxed warning. This significant update highlights the risk of thyroid C-cell tumors, which were observed in rodents treated with semaglutide at clinically relevant exposures.
Background
Ozempic, which contains the active ingredient semaglutide, is a medication available in various formulations, including Wegovy and Rybelsus. As a regulated pharmaceutical product, its label is periodically updated by the U.S. Food and Drug Administration (FDA) to reflect the latest safety information and ensure appropriate use by healthcare professionals and patients. This process ensures that all known risks, such as the potential for thyroid C-cell tumors, are clearly communicated.
What this means
The inclusion of a boxed warning, also known as a black box warning, on the Ozempic label signifies the FDA's highest level of caution for a drug. This warning specifically addresses the risk of thyroid C-cell tumors. The data supporting this warning indicates that in rodent studies, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors when administered at clinically relevant exposures. While these findings are significant, the label explicitly states that it is unknown whether Ozempic causes thyroid C-cell tumors in humans. This critical distinction means that while a potential risk has been identified in preclinical models, its direct applicability to human patients has not been established. Healthcare providers are now formally alerted to this potential risk and should consider it when prescribing Ozempic. Patients should also be informed about this warning, allowing for a more comprehensive discussion of potential benefits and risks associated with the medication. The warning underscores the importance of ongoing pharmacovigilance and further research to clarify the human relevance of these preclinical findings.
Source
The information regarding this label revision was obtained from the U.S. Food and Drug Administration (FDA) via DailyMed. The revised label, effective 2026-05-19, is accessible on dailymed.nlm.nih.gov.